ProfileGDS5678 / 1433675_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 84% 85% 88% 87% 86% 86% 84% 87% 91% 88% 84% 87% 86% 87% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.2206684
GSM967853U87-EV human glioblastoma xenograft - Control 26.4721185
GSM967854U87-EV human glioblastoma xenograft - Control 36.8548188
GSM967855U87-EV human glioblastoma xenograft - Control 46.8714487
GSM967856U87-EV human glioblastoma xenograft - Control 56.5366686
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.3460686
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.057984
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.6620887
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.4044891
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.8801488
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.146784
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.8076687
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.5691186
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.7023887